How Does Elahere Work? Mechanism of Action Explained in Plain English

Elahere (mirvetuximab soravtansine-gynx) is a type of cancer drug called an antibody-drug conjugate (ADC). It works very differently from traditional chemotherapy, which attacks all rapidly dividing cells in the body. Instead, Elahere is designed to seek out ovarian cancer cells specifically and deliver a cancer-killing drug directly to them. Here's a plain-English explanation of how it works.

What Is an Antibody-Drug Conjugate (ADC)?

Think of an ADC as a targeted missile. It has three components:

A targeting antibody — a protein that locks onto a specific target on cancer cells.

A potent drug (payload) — a chemotherapy molecule that kills cells when released inside them.

A linker — a chemical bridge connecting the antibody to the drug, designed to stay stable in the bloodstream but release the drug once inside a cancer cell.

This design means the chemotherapy is delivered directly to cancer cells — sparing many healthy cells from its toxic effects.

Step 1: The Target — Folate Receptor Alpha (FRα)

Elahere's antibody targets a protein on the surface of cancer cells called folate receptor alpha, or FRα. FRα is a receptor that cells use to take up folate (a B vitamin). In normal tissue, FRα is found in small amounts. But in many ovarian cancers, the cancer cells produce far more FRα than normal — they "overexpress" it.

About 80% of high-grade serous ovarian cancers — the most common type — overexpress FRα. About 35% have very high levels (which are the best candidates for Elahere). This makes FRα an excellent "address" for Elahere to find and attach to cancer cells.

Step 2: Binding and Internalization

When Elahere is infused into the body, the antibody component (mirvetuximab) circulates through the bloodstream until it finds cancer cells with FRα on their surface. It locks onto FRα like a key fitting a lock.

Once bound, the cancer cell does what it normally does with anything bound to FRα — it pulls the entire complex inside itself (this is called receptor-mediated endocytosis, or internalization). Think of it as the cancer cell accidentally swallowing the missile.

Step 3: Payload Release — DM4 Kills the Cell

Inside the cancer cell, the acidic environment triggers the cleavable linker to break, releasing the drug payload — DM4. DM4 is a maytansinoid, a member of a class of extremely potent tubulin-disrupting agents derived from a plant natural product. DM4 is far too toxic to use as a standalone drug (which is why it's packaged inside the ADC for targeted delivery).

DM4 works by binding to tubulin — a protein that cancer cells need to divide. When DM4 disrupts tubulin, the cancer cell can no longer complete cell division. The cell's internal structures fall apart, and the cell dies. This is called mitotic arrest.

The Three Components of Elahere Up Close

Antibody (mirvetuximab): An IgG1 monoclonal antibody designed to specifically recognize and bind FRα.

Linker (sulfo-SPDB): A cleavable disulfide linker that keeps DM4 attached to the antibody in the blood but releases it inside cells.

Payload (DM4): A maytansinoid that disrupts tubulin and kills dividing cells. An average of 3.4 DM4 molecules are attached to each antibody molecule.

Why Is This Better Than Regular Chemotherapy?

Traditional chemotherapy attacks all rapidly dividing cells — both cancer cells and healthy ones like hair follicles, gut lining, and bone marrow. This is why chemo often causes hair loss, nausea, and blood count drops. Because Elahere delivers DM4 specifically to FRα-expressing cancer cells, healthy cells that don't have FRα are largely protected. In clinical trials, patients on Elahere experienced:

Minimal hair loss (alopecia)

Much less severe bone marrow suppression compared to standard chemo

Better quality of life scores than those receiving paclitaxel, PLD, or topotecan

However, because FRα is also present in some normal tissues — particularly in the eye — ocular side effects are a notable unique concern with Elahere, requiring mandatory eye monitoring during treatment.

Why Does FRα Testing Matter Before Treatment?

Because Elahere only works on cells that have FRα on their surface, patients must be tested to confirm their tumor has sufficient FRα expression before starting treatment. This is done with the VENTANA FOLR1 (FOLR-2.1) RxDx Assay — an FDA-approved companion diagnostic test. Only patients with confirmed high FRα expression are eligible for and likely to benefit from Elahere.

For a broader overview of Elahere, see: What Is Elahere? Uses, Dosage, and What You Need to Know in 2026.

Looking for an infusion center that administers Elahere? medfinder can help find facilities near you.